Literature DB >> 8158113

Cytomegalovirus infection and allospecific cytotoxic activity of graft-infiltrating cells after heart transplantation.

A J Ouwehand1, A H Balk, C C Baan, L M Vaessen, N H Jutte, E Bos, F H Claas, W Weimar.   

Abstract

We have investigated whether cytomegalovirus (CMV) infection has an effect on donor directed cytotoxicity of graft-infiltrating cells in human heart transplants. Our study group consisted of 89 heart transplant recipients. Thirty-eight (43%) showed signs of CMV infection; in 28 of them, cytolytic activity of biopsy derived cultures could be tested during the infection. Eight patients had a primary and 20 a secondary infection. We found that during CMV infection, both primary and secondary, a significantly higher proportion of the biopsy-derived cultures showed cytotoxicity against donor HLA antigens (chi 2 test; P < 0.01 in comparison with 51 patients without infection). This was most evident in patients with both infection and acute rejection episodes when compared to patients with only one of these complications. This suggests that one process amplifies the other with regard to the up-regulation of alloreactivity within the transplanted heart. In secondary infections, only an increase of donor class I-directed cytotoxicity was found, while in primary infections cytotoxicity against donor class I and II antigens was increased (P < 0.005 vs. secondary infection).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158113     DOI: 10.1002/jmv.1890420214

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  1 in total

1.  Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.

Authors:  Javier Carbone; Nallibe Lanio; Antonio Gallego; Florian Kern; Joaquin Navarro; Patricia Muñoz; Roberto Alonso; Pilar Catalán; Juan Fernández-Yáñez; Jesús Palomo; Manuel Ruiz; Eduardo Fernández-Cruz; Elizabeth Sarmiento
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.